Nacka Strand, Sweden

Niklas Ahlborg


Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2020

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Niklas Ahlborg: Innovator in Immunology

Introduction

Niklas Ahlborg is a prominent inventor based in Nacka Strand, Sweden. He has made significant contributions to the field of immunology, particularly in the development of therapeutic methods for immune-related conditions. His innovative work has led to the filing of a patent that addresses critical health issues.

Latest Patents

Niklas Ahlborg holds a patent for a composition, kit, and method for the inhibition of IL-21 mediated activation of human cells. This patent, which is crucial for the treatment of various immune-related diseases, includes a synergistic composition that comprises two agents. The first agent is an antibody or antibody fragment directed to a first epitope of IL-21, while the second agent targets a second epitope of IL-21. This invention aims to inhibit and/or neutralize IL-21 mediated activation of human cells, which is essential for the prophylaxis and treatment of inflammatory diseases, autoimmunity, and lymphomas. He has 1 patent to his name.

Career Highlights

Niklas Ahlborg is associated with Mabtech AB, a company known for its advancements in immunological research and diagnostics. His work at Mabtech AB has allowed him to focus on innovative solutions that address pressing health challenges.

Collaborations

Niklas collaborates with Staffan Paulie, who is also involved in the field of immunology. Their partnership enhances the research and development efforts at Mabtech AB.

Conclusion

Niklas Ahlborg's contributions to immunology through his patent and work at Mabtech AB highlight his commitment to advancing medical science. His innovative approaches are paving the way for new treatments for immune-related conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…